Drugs / LANERKITUG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05537740 | Oct 2022 → Apr 2027 expected | cancer | Bayer | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LANERKITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068127 ↗ |
| Known as | BAY 3375968 | “Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.” PMID 38856863 ↗ Jun 2024 |
| Action | Deplete | “Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968” PMID 38856863 ↗ Jun 2024 |
| Modality | Monoclonal antibody | — CHEMBL6068127 ↗ |